National Institutes of Health
Division of US Department of Health and Human Services
Latest From National Institutes of Health
Compass raises $132m in Series A as it moves from screening to the clinic, and start-up HotSpot Therapeutics comes out of stealth mode with a $45m Series A financing co-led by Atlas Venture and Sofinnova Partners.
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
Though vastly underreported, new cases of Lyme in the US total more than 300,000 a year; its incidence now exceeds infections for far more visible conditions like HIV. A higher profile for Lyme is hobbled by a slow and distorted institutional response, especially among clinicians who disagree on whether Lyme is one disease or a complex constellation of many – much like cancer, but without the commitment.
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.